Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.
Cardiovasc Diabetol
; 19(1): 115, 2020 07 22.
Artículo
en Inglés
| MEDLINE | ID: covidwho-662457
ABSTRACT
The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Glucemia
/
Infecciones por Coronavirus
/
Diabetes Mellitus Tipo 2
/
Incretinas
/
Betacoronavirus
/
Hipoglucemiantes
/
Insulina
Tipo de estudio:
Estudios diagnósticos
/
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Cardiovasc Diabetol
Asunto de la revista:
Angiología
/
Cardiología
/
Endocrinologia
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
S12933-020-01090-9
Similares
MEDLINE
...
LILACS
LIS